Tag: AbbVie

AQUIPTA® (atogepant) is now approved in the European Union for the acute treatment of migraine in adults, with or without aura, and for the...

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

New $195 million facility will further enhance AbbVie's active pharmaceutical ingredient (API) production capacity and capabilities in the U.S.Expansion is part of AbbVie's previously announced commitment...

NEW YORK, Aug. 11, 2025 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the...

The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and...

The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and...

The CLK inhibitors market is projected to expand in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of these...

The CLK inhibitors market is projected to expand in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of these...

The vitiligo market is witnessing steady growth due to rising disease awareness, improved diagnostic capabilities, and advancements in treatment options such as JAK inhibitors...

The TYK2 inhibitor market is expected to witness substantial growth in the coming years, driven by the increasing prevalence of autoimmune diseases, robust clinical...

Embracing Innovation in Tenosynovitis Treatment: The global Tenosynovitis market is advancing rapidly, driven by the rising prevalence of inflammatory diseases like rheumatoid arthritis. As aging populations increase, demand grows for effective treatments to manage this tendon sheath inflammation. Biologic and targeted therapies, including TNF and IL-6 inhibitors, are at the forefront, alongside non-invasive options like PRP therapy. Leading companies such as Pfizer and AbbVie are fueling innovation with personalized medicine, addressing challenges of early diagnosis and treatment accessibility. Discover the future of tenosynovitis care and market trends shaping this evolving landscape.

Embracing Innovation in Tenosynovitis Treatment: The global Tenosynovitis market is advancing rapidly, driven by the rising prevalence of inflammatory diseases like rheumatoid arthritis. As aging populations increase, demand grows for effective treatments to manage this tendon sheath inflammation. Biologic and targeted therapies, including TNF and IL-6 inhibitors, are at the forefront, alongside non-invasive options like PRP therapy. Leading companies such as Pfizer and AbbVie are fueling innovation with personalized medicine, addressing challenges of early diagnosis and treatment accessibility. Discover the future of tenosynovitis care and market trends shaping this evolving landscape.